)
Visual24 Oct 2025
The rise of Alphabet
Cadrenal Therapeutics (CVKD) investor relations material
Cadrenal Therapeutics Lytham Partners Fall 2025 Investor Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Lytham Partners Fall 2025 Investor Conference summary30 Sep, 2025
Company overview and market focus
Focuses on developing novel anticoagulant drugs targeting high-risk and orphan indications within the $38B global oral anticoagulation market, specifically a $2B U.S. segment.
Avoids markets dominated by direct oral anticoagulants, instead addressing end-stage kidney disease, left ventricular assist devices, and mechanical heart valves.
Lead products are tecarfarin, a next-generation vitamin K antagonist, and frunexian, an IV Factor XIa inhibitor for acute care.
Tecarfarin program updates
Tecarfarin is not metabolized by the hepatic cytochrome P450 system, offering more predictable drug levels and fewer drug-drug interactions.
Holds orphan drug and fast track designations for ESKD, AFib, and LVADs, with seven years of exclusivity post-approval.
Phase II/III ready, with drug product manufactured and a phase II study in dialysis patients planned for early 2026.
EmbraceAC study showed tecarfarin matched or outperformed intensively managed warfarin, especially in patients with abnormal metabolism or drug interactions.
Demonstrated stable drug levels in severe kidney disease, unlike warfarin, supporting its use in high-risk populations.
Frunexian acquisition and acute care focus
Frunexian is a fast-on, fast-off IV Factor XIa inhibitor, uniquely positioned for acute care applications such as complex cardiac surgery.
Only Factor XIa inhibitor in development for acute care, with two completed phase I studies.
2026 goals include formulation optimization and advancing towards clinical trials for complex cardiac surgery.
Tecarfarin's advantage for ESKD/AFib patients?
Fornixum's unique role in acute care settings?
Strategic goal of Tecarfarin's Phase 2 dialysis study?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Cadrenal Therapeutics earnings date
Q3 20256 Nov, 2025
Next Cadrenal Therapeutics earnings date
Q3 20256 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Cadrenal Therapeutics, Inc. is a biopharmaceutical company focused on the development of tecarfarin, an advanced oral anticoagulant. Tecarfarin is designed to prevent heart attacks, strokes, and deaths caused by blood clots, particularly in patients with rare cardiovascular conditions that require long-term anticoagulation therapy. These conditions include end-stage kidney disease (ESKD), atrial fibrillation, and complications related to left ventricular assist devices (LVADs). The company aims to address the limitations of existing anticoagulants like warfarin, offering a more stable and reliable treatment option through an alternative metabolic pathway. The company is headquartered in Ponte Vedra, Florida, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage